Why CareDx's Naveris Link and Strong Testing Growth Make CDNA a Buy
CareDx is reshaping itself into a higher-growth testing services and digital-solutions company. Recent preliminary results showing 39% revenue growth (Testing Services +48%) and the $170M sale of Lab Products give the company financial flexibility. Coupled with early momentum tied to Naveris integration, I view the risk/reward as attractive from cu…